

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17611 A1

(51) International Patent Classification⁷: A61N 2/04, 2/00

(21) International Application Number: PCT/SE00/01730

(22) International Filing Date:
7 September 2000 (07.09.2000)

(25) Filing Language: Swedish

(26) Publication Language: English

(30) Priority Data:
9903185-8 8 September 1999 (08.09.1999) SE

(71) Applicant (for all designated States except US): EUROPEAN INSTITUTE OF SCIENCE AB [SE/SE]; Ideon, S-223 70 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FREDRIKSSON, Sarah [SE/SE]; Möllarevägen 1, S-245 61 Staffanstorp (SE). KRIZ, Dario [SE/SE]; Bosjökloster Bomhuset, S-243 95 Höör (SE).

(74) Agent: AWAPATENT AB; Box 5117, S-200 71 Malmö (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DEVICE FOR THERAPEUTIC PURPOSES ON HUMAN TISSUE, FOR INFLUENCING INJECTED MAGNETIC PARTICLES WITH AN ALTERNATING ELECTRO-MAGNETIC GRADIENT FIELD



(57) Abstract: A new device for therapeutic influence, change, decomposition of various biological structures in vivo or in vitro by means of an externally applied alternating magnetic gradient field is described.

WO 01/17611 A1

DEVICE FOR THERAPEUTIC PURPOSES ON HUMAN TISSUE;
FOR INFLUENCING INJECTED MAGNETIC PARTICLES WITH
AN ALTERNATING ELECTRO-MAGNETIC GRADIENT FIELD.

The present invention relates to equipment for changing, weakening or destroying biological structures in vivo and in vitro by means of a magnetic gradient field.

5 BACKGROUND OF THE INVENTION

Magnetism and magnetically responsible particles have been used for a long time in various biochemical and medical applications. When paramagnetic materials are exposed to an externally alternating homogeneous magnetic
10 field, heat is generated due to hysteresis. This generation of heat, in particular in combination with superparamagnetic nanoparticles, is used in cancer therapy and is then referred to as magnetic fluid hyperthermia (1). A cancer cell normally has a higher temperature than a
15 healthy cell and therefore does not tolerate as high a temperature rise as a healthy cell. Thus, the cancer cells can be selectively destroyed or weakened without affecting the host organism. An alternative method is that the composition of the superparamagnetic particles
20 is of such type that cancer cells are made to take in said particles into the cell, whereby the temperature is raised more efficiently in the cancer cell without any considerable heat loss to the environment. This type of therapy has been found to be promising, which is de-
25 scribed, inter alia, in the patent literature (2, 3, 4, 5), even if there is no clinically approved magnetic equipment for this purpose for the time being.

A cell membrane is, inter alia, composed of lipids and fatty acids, which both have poor thermal conductivity, which makes it difficult to fight the target cell
30 efficiently with only extracellular heat generated by hysteresis.

SUMMARY OF THE INVENTION

According to the present invention, a device is provided which solves the above-mentioned problems. Thus, a device is provided for increasing the thermal and/or kinetic energy of magnetically responsible particles, said device containing at least two magnetic field generating means, of which at least one is a coil, between which means an alternating magnetic gradient field can be generated in a spatially defined area, into which spatially defined area human or animal tissue can be introduced, said alternating magnetic gradient field causing an increase of the thermal and/or kinetic energy of magnetically responsible particles which have been added to said tissue, the increased thermal and/or kinetic energy of the magnetically responsible particles selectively reducing, deactivating or destroying endogenous or exogenous biological structures in said tissue.

In one embodiment of the invention, one of the magnetic field generating means is a permanent magnet.

In another embodiment of the invention, the device contains at least two coils and these coils are fed with alternating currents having different frequencies and/or amplitudes and/or phases, or alternatively said coils are fed with either the positive or the negative part of the fed alternating current.

Furthermore, the device can suitably be equipped with a thermostat for careful temperature control of said tissue and/or with variable time setting for careful control of the time during which said tissue is exposed to the alternating magnetic gradient field.

In one embodiment of the device, the alternating magnetic gradient field alternates with frequencies of up to 30 MHz and the field strength inside said coils amounts to at least 10 mT.

The tissue which is to be treated can be a body part or an inner organ or blood, which are returned to the

host organism after completed exposure to the alternating magnetic gradient field.

The magnetically responsible particles suitably comprise a core of a metal oxide and a coating containing
5 antibodies or parts thereof and have a size of 0.1-300 nm.

The magnetically responsible particles have been added to the host organism before the exposure of its tissue to the alternating magnetic gradient field, or
10 alternatively after the tissue has been temporarily removed from the host organism.

The endogenous or exogenous biological structures consist, for instance, of mammal cells, malignant cells, plant cells, nerve cells, bacteria, viruses, cellular
15 organelles, cell membranes, cell walls, liposomes, proteins, protozoa, parasites, peptides, drugs, toxins, organic compounds, inorganic compounds, or combinations thereof.

According to one aspect, the device is intended for
20 in vivo or in vitro treatment of tumour diseases, endocrine disorders or infectious diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic illustration of the behaviour of magnetically responsible materials in one embodiment
25 of the device according to the invention.

Fig. 2 is a schematic illustration of the structure of one embodiment of the device according to the invention for generating a magnetic gradient field with alternating gradient direction.

30 Fig. 3 is an illustration of an electronic circuit which can be used to feed the coils in one embodiment of the device according to the invention with alternating current.

DETAILED DESCRIPTION OF THE INVENTION

35 By the present invention, a new device is provided for use in a completely new method which combines the generation of heat by hysteresis with a powerful intro-

duction of shearing forces. The shearing forces initiate dislocations in the biological structure, for instance in cell membranes, cell walls (in cases where the target cell is e.g. a bacterium) or in intracellular components
5 due to mechanical fatigue, which causes damage in the structures. The method is based on the use of an externally applied gradient magnetic field.

Below, the invention will be described in more detail by means of the drawings, which show embodiments of
10 the invention.

Fig. 1 illustrates how a magnetically responsible particle is affected by a magnetic gradient field. Without the action of an external magnetic field, the dipoles
15 in the magnetically responsible particles are randomly oriented (Fig. 1A). When the particles are exposed to a homogeneous magnetic field 2, the dipoles are oriented according to the direction of the field (Fig. 1B). When the direction of the homogeneous field alternates, the dipoles will alternate according to the field direction
20 of the external homogeneous field. When the applied magnetic field is non-homogeneous, i.e. is a gradient magnetic field 3, the dipoles in the magnetically responsible particles will be aligned with the field direction at the same time as the magnetically responsible particles will move towards the gradient according to
25 Fig. 1C.

Furthermore, by alternating the direction of the gradient, the magnetically responsible particle can be brought into mechanical vibration (due to the influence
30 of forces it will alternately change directions).

Moreover, a combination of said magnetic gradient field with a homogeneous magnetic field can be provided either simultaneously or with a time shift so that a better orientation of the dipoles and greater shearing
35 forces can be obtained.

The generation of a gradient magnetic field whose direction periodically alternates (periodically shifts)

requires a device according to the invention, for instance, as illustrated in Fig. 2. The functional principle is based on two coils A and B (with or without a ferrite core) being placed opposite to each other. A control unit C controls the current through the coils so that only one of the coils at a time has a current flowing through its windings. This alternation of current, whose frequency is controlled by the oscillator (OSC), causes the coils to alternately create the gradient magnetic fields D and E with different gradient directions. A biological structure or a magnetically responsible particle P located between the coils will be exposed to a gradient magnetic field with periodically alternating direction, which will induce a mechanical vibration according to the description above.

The present invention also comprises variants, in which, for instance, the current intensity or its direction through the windings of the coils can be controlled so that more efficient vibrations can be obtained. A very useful special case is to let the gradient direction alternate but maintain the orientation of the dipoles by always letting the field direction be the same. This results in advantages, such as no provision of hysteresis (no generation of heat), while the vibration frequency (=kinetic energy) can be increased since the alternation rate of the dipoles will not be limited by the tendency of the magnetic material to counteract the alternation of the dipole directions.

It is also possible to introduce additional coils to obtain more efficient or more directional vibrations.

Fig. 3 illustrates an example of an electronic circuit which can be used to feed the coils in the device according to the invention with alternating current. The circuit contains an oscillator 4 based on the circuit XR2206, whose output signal 5 is amplified by a power amplifying step 6, which is connected in parallel and based on 5 circuits of the type PBD 3548/1 (manufactured

by Ericsson), whose output signal 7 can drive an alternating current (maximum 1 MHz, 10 A) through one or more coils.

5 It is obvious to the one skilled in the art that the above-described electronic circuit in Fig. 3 is easy to modify and that the same result can be obtained by means of various alternative prior-art connections of oscillators and power amplifiers.

10 One example of the connection of the coils is that each coil constitutes a part of an oscillation circuit consisting of a $0.5\ \Omega$ resistor, a 127 pF capacitor and a 200 μH coil, which are connected in series, which oscillation circuit is fed with alternating current such as shown in Fig. 3.

15 An alternating gradient field is obtained between two coils which are part of said oscillation circuit and applied to an electronic circuit each, as shown in Fig. 3, with the difference, however, that the coils are fed with 1.0 MHz and 0.9 MHz, respectively. The variation
20 of the gradient field will be dependent on the difference frequency 1.0 MHz - 0.9 MHz.

It is obvious to the one skilled in the art that the above-described example is easy to modify and that the same result can be achieved by means of various alternative
25 native connections and coils.

REFERENCES

1. Jordan A., Wust P., Scholz R., Faehling H., Krause J. & Felix R. Magnet Fluid Hyperthermia, 569-597, in Scientific and Clinical Applications of Magnetic Carriers,
5 edited by Häfeli U., Schutt W., Teller J. and Zborowski M. Plenum Press 1997.
2. Gordon R.T. Cancer treatment. US Patent No. 4,303,636, 1981.
- 10 3. Gordon R.T. Cancer treatment method. US Patent No. 4,662,952, 1986.
4. Gordon R.T. Use of magnetic susceptibility probes in the treatment of cancer. US Patent No. 4,662,359, 1987.
5. Borelli N.F., Luderer A.A. & Panzarino J. N. Radio
15 frequency induced hyperthermia for tumor therapy. US Patent No. 4,323,056, 1982.

CLAIMS

1. A device for increasing the thermal and/or
5 kinetic energy of magnetically responsible particles,
c h a r a c t e r i s e d in that it contains at least two
magnetic field generating means, of which at least one is
a coil, between which means an alternating magnetic gra-
dient field can be generated in a spatially defined area,
10 into which spatially defined area human or animal tissue
can be introduced, said alternating magnetic gradient
field causing an increase of the thermal and/or kinetic
energy of magnetically responsible particles which have
been added to said tissue, the increased thermal and/or
15 kinetic energy of the magnetically responsible particles
selectively reducing, deactivating or destroying endoge-
nous or exogenous biological structures in said tissue.

2. A device as claimed in claim 1, c h a r a c -
t e r i s e d in that one of the magnetic field generat-
20 ing means is a permanent magnet.

3. A device as claimed in claim 1 or 2, c h a r -
a c t e r i s e d in that it contains at least two coils,
and that these coils are fed with alternating currents
having different frequencies and/or amplitudes and/or
25 phases, or alternatively that said coils are fed with
either the positive or the negative part of the fed
alternating current.

4. A device as claimed in one or more of claims 1-3,
c h a r a c t e r i s e d in that it is equipped with a
30 thermostat for careful temperature control of said tis-
sue, and/or that it is equipped with variable time set-
ting for careful control of the time during which said
tissue is exposed to the alternating magnetic gradient
field.

35 5. A device as claimed in one or more of claims 1-4,
c h a r a c t e r i s e d in that the alternating magnetic
gradient field alternates with frequencies of up to

30 MHz, and that the field strength inside said coils amounts to at least 10 mT.

6. A device as claimed in one or more of claims 1-5, characterised in that said tissue consists of
5 a body part or an inner organ or blood, which are returned to the host organism after completed exposure to the alternating magnetic gradient field.

7. A device as claimed in one or more of claims 1-6, characterised in that said magnetically re-
10 sponsible particles comprise a core of a metal oxide and a coating containing antibodies or parts thereof and have a size of 0.1 - 300 nm.

8. A device as claimed in one or more of claims 1-7, characterised in that said magnetically re-
15 sponsible particles have been added to the host organism before the exposure of its tissue to the alternating magnetic gradient field, or alternatively that said magnetically responsible particles have been added to the tissue after the tissue has been temporarily removed from the
20 host organism.

9. A device as claimed in one or more of claims 1-8, characterised in that said endogenous or exogenous biological structures consist of mammal cells, malignant cells, plant cells, nerve cells, bacteria,
25 viruses, cellular organelles, cell membranes, cell walls, liposomes, proteins, protozoa, parasites, peptides, drugs, toxins, organic compounds, inorganic compounds, or combinations thereof.

10. A device as claimed in one or more of claims 1-
30 9, characterised in that it is intended for in vivo or in vitro use for treating tumour diseases, endocrine disorders or infectious diseases.

1/3

FIG. 1A




FIG. 1B






FIG. 1C




Figur 1

2/3



Figur 2

3/3



Figur 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01730

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61N 2/04, A61N 2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4983159 A (R.W. RAND), 8 January 1991 (08.01.91), column 3, line 38 - line 52 --	1-10
X	US 4303636 A (R.T. GORDON), 1 December 1981 (01.12.81), column 3, line 14 - line 41 --	1-10
A	JP 11057031 A 19990302 (DAIICHI KOSHUHA KOGYO KK) 1999-03-02 (abstract) World Patents Index (online). London.U.k.: Derwent Publications, Ltd. (retrieved on 2000-12-057). Retrieved from: EPO WPI Database. DW199919, Accession No. 99-222966 --	1-10

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 December 2000

Date of mailing of the international search report

13 -12- 2000

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrik Blidefalk/AE
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01730

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4662359 A (R.T. GORDON), 5 May 1987 (05.05.87) --	1-10
A	RU2080133 C1 (RESHETOV V A) 1997-05-27 (abstract)World Patents Index(online). London, U.K.: Derwent Publications, Ltd. (retrieved on 2000-12-05).Retrieved from: EPO WPI Database, DW199806, Accession No. 1998-061300 -- -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/11/00

International application No.

PCT/SE 00/01730

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	4983159	A	08/01/91	NONE	
US	4303636	A	01/12/81	US 4106488 A	15/08/78
US	4662359	A	05/05/87	NONE	